1. Amatore C, Arbault S, Bonifas I, et al. Correlation between vesicle quantal size and fusion pore release in chromaffin cell exocytosis. Biophys J. 2005;88(6):4411-20.
2. Antunes F, Han D, Rettori D, Cadenas E. Mitochondrial damage by nitric oxide is potentiated by dopamine in PC12 cells. Biochim Biophys Acta. 2002;1556(2-3):233-8.
3. Barzilai A, Daily D, Zilkha-Falb R, et al. The molecular mechanisms of dopamine toxicity. Adv Neurol. 2003;91:73-82.
4. Becker OM, Marantz Y, Shacham S, et al. G protein-coupled receptors: in silico drug discovery in 3D. Proc Natl Acad Sci U S A. 2004;101(31):11304-9.
5. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev. 2001;22(6):724-63.
6. Binda C, Hubalek F, Li M, Edmondson DE, Mattevi A. Crystal structure of human monoamine oxidase B, a drug target enzyme monotopically inserted into the mitochondrial outer membrane. FEBS Lett. 2004;564(3):225-8.
7. Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A. Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002;9(1):22-6.
8. Biskup S, Moore DJ, Rea A, et al. Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 2007;8:102.
9. Bjerggaard C, Fog JU, Hastrup H, et al. Surface targeting of the dopamine transporter involves discrete epitopes in the distal C terminus but does not require canonical PDZ domain interactions. J Neurosci. 2004;24(31):7024-36.
10. Boehmler W, Obrecht-Pflumio S, Canfield V, Thisse C, Thisse B, Levenson R. Evolution and expression of D2 and D3 dopamine receptor genes in zebrafish. Dev Dyn. 2004;230(3):481-93.
11. Brautigam M, Kittner B, Herken H. Evaluation of neurotropic drug actions on tyrosine hydroxylase activity and dopamine metabolism in clonal cell lines. Arzneimittelforschung. 1985;35(1A):277-84.
12. Brice A. Genetics of Parkinson's disease: LRRK2 on the rise. Brain. 2005;128(Pt 12):2760-2.
13. Briegleb SK, Gulley JM, Hoover BR, Zahniser NR. Individual differences in cocaine- and amphetamine-induced activation of male Sprague-Dawley rats: contribution of the dopamine transporter. Neuropsychopharmacology. 2004;29(12):2168-79.
14. Burke WJ, Li SW, Williams EA, Nonneman R, Zahm DS. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis. Brain Res. 2003;989(2):205-13.
15. Cabrera-Vera TM, Hernandez S, Earls LR, et al. RGS9-2 modulates D2 dopamine receptor-mediated Ca2+ channel inhibition in rat striatal cholinergic interneurons. Proc Natl Acad Sci U S A. 2004;101(46):16339-44.
16. Caudle WM, Colebrooke RE, Emson PC, Miller GW. Altered vesicular dopamine storage in Parkinson's disease: a premature demise. Trends Neurosci. 2008;31(6):303-8.
17. Caudle WM, Richardson JR, Wang MZ, et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci. 2007;27(30):8138-48.
18. Chambers I, Colby D, Robertson M, et al. Functional expression cloning of Nanog, a pluripotency sustaining factor in embryonic stem cells. Cell. 2003;113(5):643-55.
19. Chen K, Wu HF, Shih JC. Influence of C terminus on monoamine oxidase A and B catalytic activity. J Neurochem. 1996;66(2):797-803.
20. Chen L, Ding Y, Cagniard B, et al. Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci. 2008;28(2):425-33.
21. Chen X, Zhang J, Zhai H, Chen X, Hu Z. Determination of levodopa by capillary zone electrophoresis using an acidic phosphate buffer and its application in the analysis of beans. Food Chem.2005;92:381–86
22. Cohen G, Farooqui R, Kesler N. Parkinson disease: a new link between monoamine oxidase and mitochondrial electron flow. Proc Natl Acad Sci U S A. 1997;94(10):4890-4.
23. Colliver TL, Pyott SJ, Achalabun M, Ewing AG. VMAT-Mediated changes in quantal size and vesicular volume. J Neurosci. 2000;20(14):5276-82.
24. Conway KA, Lee SJ, Rochet JC, Ding TT, Williamson RE, Lansbury PT, Jr. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A. 2000;97(2):571-6.
25. Conway KA, Rochet JC, Bieganski RM, Lansbury PT, Jr. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science. 2001;294(5545):1346-9.
26. Cui HF, Ye JS, Chen Y, Chong SC, Sheu FS. Microelectrode array biochip: tool for in vitro drug screening based on the detection of a drug effect on dopamine release from PC12 cells. Anal Chem. 2006;78(18):6347-55.
27. Dalley JW, Laane K, Theobald DE, et al. Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens. Proc Natl Acad Sci U S A. 2005;102(17):6189-94.
28. De Colibus L, Li M, Binda C, Lustig A, Edmondson DE, Mattevi A. Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proc Natl Acad Sci U S A. 2005;102(36):12684-9.
29. Edmondson DE, Binda C, Mattevi A. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. Arch Biochem Biophys. 2007;464(2):269-76.
30. Feinberg EH, Vanhoven MK, Bendesky A, et al. GFP Reconstitution Across Synaptic Partners (GRASP) defines cell contacts and synapses in living nervous systems. Neuron. 2008;57(3):353-63.
31. Ferrer JV, Javitch JA. Cocaine alters the accessibility of endogenous cysteines in putative extracellular and intracellular loops of the human dopamine transporter. Proc Natl Acad Sci U S A. 1998;95(16):9238-43.
32. Fujita K, Lazarovici P, Guroff G. Regulation of the differentiation of PC12 pheochromocytoma cells. Environ Health Perspect. 1989;80:127-42.
33. Giros B, Caron MG. Molecular characterization of the dopamine transporter. Trends Pharmacol Sci. 1993;14(2):43-9.
34. Gloeckner CJ, Kinkl N, Schumacher A, et al. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet. 2006;15(2):223-32.
35. Gordito MP, Kotsis DH, Minteer SD, Spence DM. Flow-based amperometric detection of dopamine in an immobilized cell reactor. J Neurosci Methods. 2003;124(2):129-34.
36. Greene LA, Tischler AS. Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A. 1976;73(7):2424-8.
37. Hamacher A, Weigt M, Wiese M, Hoefgen B, Lehmann J, Kassack MU. Dibenzazecine compounds with a novel dopamine/5HT2A receptor profile and 3D-QSAR analysis. BMC Pharmacol. 2006;6:11.
38. Hastings TG, Lewis DA, Zigmond MJ. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A. 1996;93(5):1956-61.
39. Hastrup H, Sen N, Javitch JA. The human dopamine transporter forms a tetramer in the plasma membrane: cross-linking of a cysteine in the fourth transmembrane segment is sensitive to cocaine analogs. J Biol Chem. 2003;278(46):45045-8.
40. Hubalek F, Binda C, Khalil A, et al. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. J Biol Chem. 2005;280(16):15761-6.
41. Hubalek F, Pohl J, Edmondson DE. Structural comparison of human monoamine oxidases A and B: mass spectrometry monitoring of cysteine reactivities. J Biol Chem. 2003;278(31):28612-8.
42. Hynson RM, Kelly SM, Price NC, Ramsay RR. Conformational changes in monoamine oxidase A in response to ligand binding or reduction. Biochim Biophys Acta. 2004;1672(1):60-6.
43. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet. 2007;16(11):1319-26.
44. Imam SZ, el-Yazal J, Newport GD, et al. Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci. 2001;939:366-80.
45. Javitch JA, Snyder SH. Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol. 1984;106(2):455-6.
46. Jeanneteau F, Guillin O, Diaz J, Griffon N, Sokoloff P. GIPC recruits GAIP (RGS19) to attenuate dopamine D2 receptor signaling. Mol Biol Cell. 2004;15(11):4926-37.
47. Jin CM, Yang YJ, Huang HS, Lim SC, Kai M, Lee MK. Induction of dopamine biosynthesis by l-DOPA in PC12 cells: implications of L-DOPA influx and cyclic AMP. Eur J Pharmacol. 2008;591(1-3):88-95.
48. Kadota T, Yamaai T, Saito Y, et al. Expression of dopamine transporter at the tips of growing neurites of PC12 cells. J Histochem Cytochem. 1996;44(9):989-96.
49. Kalani MY, Vaidehi N, Hall SE, et al. The predicted 3D structure of the human D2 dopamine receptor and the binding site and binding affinities for agonists and antagonists. Proc Natl Acad Sci U S A. 2004;101(11):3815-20.
50. Kan X, Zhao Y, Geng Z, Wang Z, Zhu J-J. Composites of Multiwalled Carbon Nanotubes and Molecularly Imprinted Polymers for Dopamine Recognition. J. Phys. Chem. C 2008;112: 4849-54.
51. Khoshbouei H, Sen N, Guptaroy B, et al. N-terminal phosphorylation of the dopamine transporter is required for amphetamine-induced efflux. PLoS Biol. 2004;2(3):E78.
52. Koshimura K, Murakami Y, Tanaka J, Kato Y. The role of 6R-tetrahydrobiopterin in the nervous system. Prog Neurobiol. 2000;61(4):415-38.
53. Krygowska-Wajs A, Kachergus JM, Hulihan MM, et al. Clinical and genetic evaluation of 8 Polish families with levodopa-responsive parkinsonism. J Neural Transm. 2005;112(11):1487-502.
54. Kulkarni SS, Kopajtic TA, Katz JL, Newman AH. Comparative structure-activity relationships of benztropine analogues at the dopamine transporter and histamine H(1) receptors. Bioorg Med Chem. 2006;14(11):3625-34.
55. Lee SH, Rhee J, Koh JK, Lee YS. Species differe, nces in functions of dopamine transporter: paucity of MPP + uptake and cocaine binding in bovine dopamine transporter. J Neurosci.1996;214:199-01.

56. Lewis PA, Greggio E, Beilina A, Jain S, Baker A, Cookson MR. The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun. 2007;357(3):668-71.
57. Li HT, Lin DH, Luo XY, et al. Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration. FEBS J. 2005;272(14):3661-72.
58. Li M, Binda C, Mattevi A, Edmondson DE. Functional role of the "aromatic cage" in human monoamine oxidase B: structures and catalytic properties of Tyr435 mutant proteins. Biochemistry. 2006;45(15):4775-84.
59. Li MW, Martin RS. Microchip-based integration of cell immobilization, electrophoresis, post-column derivatization, and fluorescence detection for monitoring the release of dopamine from PC 12 cells. Analyst. 2008;133(10):1358-66.
60. Liu Z, Wang X, Yu Y, et al. A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A. 2008;105(7):2693-8.
61. Lu G, Unge T, Owera-Atepo JB, Shih JC, Ekblom J, Oreland L. Characterization and partial purification of human monoamine oxidase-B expressed in Escherichia coli. Protein Expr Purif. 1996;7(3):315-22.
62. Lynn DE, Lubke G, Yang M, et al. Temperament and character profiles and the dopamine D4 receptor gene in ADHD. Am J Psychiatry. 2005;162(5):906-13.
63. Mosharov EV, Gong LW, Khanna B, Sulzer D, Lindau M. Intracellular patch electrochemistry: regulation of cytosolic catecholamines in chromaffin cells. J Neurosci. 2003;23(13):5835-45.
64. Nandigama RK, Edmondson DE. Influence of FAD structure on its binding and activity with the C406A mutant of recombinant human liver monoamine oxidase A. J Biol Chem. 2000;275(27):20527-32.
65. Newton-Vinson P, Hubalek F, Edmondson DE. High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr Purif. 2000;20(2):334-45.
66. Norregaard L, Loland CJ, Gether U. Evidence for distinct sodium-, dopamine-, and cocaine-dependent conformational changes in transmembrane segments 7 and 8 of the dopamine transporter. J Biol Chem. 2003;278(33):30587-96.
67. Okumoto S, Looger LL, Micheva KD, Reimer RJ, Smith SJ, Frommer WB. Detection of glutamate release from neurons by genetically encoded surface-displayed FRET nanosensors. Proc Natl Acad Sci U S A. 2005;102(24):8740-5.
68. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. 2004;19(9):997-1005.
69. Ostergren A, Lindquist NG, Brittebo EB. Differential effects of dopamine melanin on norharman-induced toxicity in PC12 cells. J Neural Transm. 2007;114(7):909-18.
70. Ostergren A, Svensson AL, Lindquist NG, Brittebo EB. Dopamine melanin-loaded PC12 cells: a model for studies on pigmented neurons. Pigment Cell Res. 2005;18(4):306-14.
71. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB. Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci. 2007;27(12):3338-46.
72. Rashid AJ, So CH, Kong MM, et al. D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum. Proc Natl Acad Sci U S A. 2007;104(2):654-9.
73. Rebrin I, Geha RM, Chen K, Shih JC. Effects of carboxyl-terminal truncations on the activity and solubility of human monoamine oxidase B. J Biol Chem. 2001;276(31):29499-506.
74. Sai Y, Wu Q, Le W, Ye F, Li Y, Dong Z. Rotenone-induced PC12 cell toxicity is caused by oxidative stress resulting from altered dopamine metabolism. Toxicol In Vitro. 2008;22(6):1461-8.

75. Shi B, Huang W, Cheng J. Determination of neurotransmitters in PC 12 cells by microchip electrophoresis with fluorescence detection. Electrophoresis. 2007;28(10):1595-600.
76. Shi L, Javitch JA. The second extracellular loop of the dopamine D2 receptor lines the binding-site crevice. Proc Natl Acad Sci U S A. 2004;101(2):440-5.
77. Smith WW, Pei Z, Jiang H, et al. Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A. 2005;102(51):18676-81.
78. So CH, Varghese G, Curley KJ, et al. D1 and D2 dopamine receptors form heterooligomers and cointernalize after selective activation of either receptor. Mol Pharmacol. 2005;68(3):568-78.
79. Tse DC, McCreery RL, Adams RN. Potential oxidative pathways of brain catecholamines. J Med Chem. 1976;19(1):37-40.
80. Ukairo OT, Bondi CD, Newman AH, et al. Recognition of benztropine by the dopamine transporter (DAT) differs from that of the classical dopamine uptake inhibitors cocaine, methylphenidate, and mazindol as a function of a DAT transmembrane 1 aspartic acid residue. J Pharmacol Exp Ther. 2005;314(2):575-83.
81. Wang L, Xie C, Greggio E, et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J Neurosci. 2008;28(13):3384-91.
82. Watson CS, Alyea RA, Hawkins BE, Thomas ML, Cunningham KA, Jakubas AA. Estradiol effects on the dopamine transporter - protein levels, subcellular location, and function. J Mol Signal. 2006;1:5.
83. Werkman TR, Kruse CG, Nievelstein H, Long SK, Wadman WJ. In vitro modulation of the firing rate of dopamine neurons in the rat substantia nigra pars compacta and the ventral tegmental area by antipsychotic drugs. Neuropharmacology. 2001;40(7):927-36.
84. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005;102(46):16842-7.
85. Wilson JM, Kish SJ. The vesicular monoamine transporter, in contrast to the dopamine transporter, is not altered by chronic cocaine self-administration in the rat. J Neurosci. 1996;16(10):3507-10.
86. Zhou ZD, Kerk SY, Xiong GG, Lim TM. Dopamine auto-oxidation aggravates non-apoptotic cell death induced by over-expression of human A53T mutant alpha-synuclein in dopaminergic PC12 cells. J Neurochem. 2009;108(3):601-10.
87. Zhu J, Bardo MT, Bruntz RC, Stairs DJ, Dwoskin LP. Individual differences in response to novelty predict prefrontal cortex dopamine transporter function and cell surface expression. Eur J Neurosci. 2007;26(3):717-28.
88. Zhu X, Babar A, Siedlak SL, et al. LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol Neurodegener. 2006;1:17.